

## **Non-Specific Pleuritis: pathological patterns in benign pleuritis**

Georgia Karpathiou<sup>1</sup>, Sirine Hathroubi<sup>1</sup>, Arnaud Patoir<sup>2</sup>, Olivier Tiffet<sup>2</sup>, Francois Casteillo<sup>1</sup>, Clement Brun<sup>3</sup>, Fabien Forest<sup>1</sup>, Najib M. Rahman<sup>4</sup>, Michel Peoc'h<sup>1</sup>, Marios E. Froudarakis<sup>3</sup>

Departments of Pathology<sup>1</sup>, Thoracic Surgery<sup>2</sup>, Pneumonology and Thoracic Oncology<sup>3</sup>  
North Hospital, University Hospital of St-Etienne, France and <sup>4</sup>Oxford Respiratory Trials  
Unit, University of Oxford UK

### **Corresponding author:**

Georgia Karpathiou MD, PhD, BSc  
Department of Pathology  
University Hospital of Saint-Etienne  
42055 CEDEX2 St-Etienne, France  
e-mail: [gakarpath@yahoo.gr](mailto:gakarpath@yahoo.gr)

**Running title:** Non specific pleuritis

**Key words:** non-specific, pleuritis, inflammation, vascular proliferation, effusion, fibrosis, mesothelial hyperplasia, thoracoscopy, fibrosis, pleural disease, biopsy, pleura

**Word count:** 2177 (main body), 165 (abstract)

**Tables:** 5 – **Figures:** 3 – **References:** 22

**Conflict of interest:** The authors have no conflict to disclose in relation to this manuscript

## **Abstract**

**Background:** A pleural biopsy without granulomatous inflammation or tumor cells is interpreted as “non-specific pleuritis” (NSP), a diagnosis without any specificity, often frustrating for physicians. However, varying histological features are found in NSPs with unknown significance. **Objectives:** To describe the detailed microscopic features of NSP and correlate them with the underlying etiology. **Material and methods:** 100 patients diagnosed with NSP after pleural biopsy, were retrospectively evaluated. A benign cause of pleural effusion was attributed. Histological features evaluated were inflammation, fibrosis, vascular proliferation, haemorrhage, fibrin, oedema and mesothelial hyperplasia. A semi-quantitative scoring was applied. **Results:** Bacterial-caused and autoimmune disease-associated NSPs showed the higher score followed by viral and drug-induced conditions, while pneumothorax and cardiac-induced NSP showed the lower score ( $p<0.0001$ ). The degree of fibrosis was higher in bacterial NSP, and the type of fibrosis was cellular in this group ( $p=0.006$ ). Vascular proliferation differed between groups ( $p<0.0001$ ), with bacterial NSP showing the higher one. **Conclusion:** Histological findings differ significantly between the varying etiologies of NSP, and this may be used to suggest identify the cause of the effusion.

## **Introduction**

The pleural cavity is a virtual space surrounding the lungs and containing a very small amount of fluid, normally less than 15 mL in a 70-kg individual (1) (2). An abnormal collection of fluid within this cavity is called pleural effusion. Pleural effusion is a common presenting feature of a wide range of pleural, pulmonary or systemic diseases, benign or malignant. Standard work-up in this case includes clinical history, physical examination, blood tests, diagnostic thoracentesis, chest radiograph and computerized tomography. Thoracoscopy will be often performed as it provides the possibility to obtain pleural tissue under direct inspection of the pleural cavity (3). Diagnostic sensitivity of thoracoscopy for malignancy reaches 95% (3).

However, in cases where a malignancy or a granulomatous disease is not histologically diagnosed, microscopic features for the rest of possible etiologies are considered largely the same, and a descriptive type of histopathological diagnosis will be employed for most of them. The term kept for these cases is “non-specific pleuritis” (NSP). After thoracoscopy, a diagnosis of NSP is rendered in 8% to 38% of the cases, with 25% of them considered 'idiopathic' with no probable cause, while almost 10% of these cases will finally reveal malignancy, particularly mesothelioma (4) (5) (6) (7). This reveals the difficulties in establishing the correct diagnosis, histologically and clinically, in NSP cases but it also highlights an important absence in our knowledge concerning this entity: there are no studies describing in detail the microscopic features of NSP and their potential correlation with the underlying etiology.

Thus, the aim of the study is to report the detailed histological features of a NSP series in order to define differences in the histopathological pattern according to the underlying disease.

## **Material and Methods**

### **Study group**

This study used information extracted from the medical electronic files of 100 consecutive patients diagnosed with NSP after pleural biopsy for recurrent undiagnosed pleural effusion at the University Hospital of Saint-Etienne from January 2014 to January 2017. Inclusion criteria were (a) a histological diagnosis of NSP excluding cases of neoplastic or granulomatous disease and (b) a minimum follow up of 12 months (8). The study was approved by the Internal Review Board of the University Hospital of Saint-Etienne (212018/CHUSTE).

Medical files were reviewed to record demographic data, clinical features, previous clinical history and comorbidities, asbestos exposure, medications and additional laboratory and investigational data. The predominant macroscopic appearance of the pleural cavity, recorded by the thoracoscopist was also documented as: inflammatory, fibrinous, septated, hemorrhagic or pleural plaques. All data were reviewed clinically to achieve a final etiological diagnosis.

### **Histopathological evaluation**

All available slides were reviewed to evaluate the following parameters: (a) inflammation, (b) fibrosis, (c) vascular proliferation (d) edema, (e) fibrin, (f) hemorrhage, (g) mesothelial hyperplasia. As no histological scoring system concerning the pleura has been established to date in humans, we used a system of an experimental model of pleural disease (9) (10). According to it, a semi-quantitative system of 0=absence, 1=mild, 2=moderate, 3=severe is applied for each parameter. A final score was attributed as the sum of all values (10).

Furthermore, concerning inflammation, the presence of all different cellular types was recorded for each case and also the predominant inflammatory cell type

(lymphocytes, plasma<sup>cytes</sup>, histiocytes, neutrophil<sup>ic</sup> granulocytes, eosinophil<sup>ic</sup> granulocytes) was separately recorded. Likewise, concerning fibrosis this was further characterized into the following types: (a) cellular, when a fibroblast-rich type fibrosis was found, (b) old, when only a well-established collagenous fibrosis poor in cells was found and (c) mixed, when both types of fibrosis were found. Moreover, the presence of prominent layering of tissue elements was recorded.

### Statistical analysis

Data were analyzed using the Stat View software (Abacus Concepts, Berkeley Ca, USA). We used the chi-square test to explore any relationship between two groups for categorical data, factorial analysis of variances (ANOVA) to consider the effect of at least one factor on a continuous parameter studied. For all analyses, statistical significance was set at a *p* value of < 0.05.

## **Results**

### Demographics

**Patients'** demographics are shown in Table 1. Age at diagnosis ranged from 13 to 94 years with a median of 63 years. Seventy-one patients were male and 29 were female. Median follow-up was 36 months. Eight patients died during the post-operative period or follow-up, none due to malignancy-associated pleural effusion. Overall, no pleural malignancy was revealed during follow-up.

The predominant macroscopic pattern during thoracoscopy was inflammatory in 40% of the cases, followed by fibrinous (14%), septated (8%), fibrous (6%) and hemorrhagic (2%). Pleural plaques, as the predominant pattern, were found in two patients (2%), whereas another 13 patients harbored histologically confirmed plaques.

Regarding final etiological diagnosis based to all available data, this included pneumothorax in 28 patients (28%) and bacterial infection in 27 patients (27%). In the

latter case, the following bacterial species were found: *Pneumococcus*, *Staphylococcus*, *Streptococcus*, *Pseudomonas*, *Hemophilus*, *Escherichia*, *Neisseria*. Viral pleural effusion was separately categorized and included 7 patients (7%). Cardiac-associated pleural effusion were 10 (10%), drug-induced 7 (7%) and of auto-immune etiology 5 (5%). Cases merged into the “Other” group (n=16, 16%), in terms of analysis, included: cases attributed to asbestos exposure (n=2), chylothorax (n=1), post-traumatic (n=2), pulmonary embolism (n=1), Dressler syndrome (n=1), post-irradiation (n=1), kidney failure (n=1), eosinophilic pleuritis (n=1), and in six cases (6%) no possible etiology was attributed. These 16 cases were excluded from further statistical analysis due to the very limited number with specific etiology or their unknown etiology.

#### Clinicopathological correlations

Histological findings are summarized in Table 2 and illustrated in Figures 1-3. Association of histological findings with effusion's aetiology is presented in Table 3. The higher final score of pathological changes was found in bacterial diseases and autoimmune ones; viral and drug-induced NSPs showed a similar moderate score while the lower score was produced by heart disease and pneumothorax ( $p<0.0001$ ).

Seen by histological feature, degree of inflammation did not differ between the different etiological groups ( $p=0.3$ ) but the predominant inflammatory cell type did differ, as in most groups lymphocytes was the predominant type while in the pneumothorax and the bacterial group, histiocytes and neutrophils, respectively, were also found ( $p=0.02$ ). The presence of histiocytes, was a feature mostly of pneumothorax and viral disease ( $p<0.0001$ ), in comparison to other etiologies.

Degree of fibrosis differed between etiological groups as the bacterial-caused group showed the most severe fibrosis ( $p=0.03$ ). Furthermore, the type of fibrosis differed as it was cellular in the bacterial-caused group in comparison to other groups, which showed an

old type of fibrosis ( $p=0.006$ ). Similarly, layering of tissue elements was more often seen with bacterial pleural effusion than the rest of the groups ( $p=0.05$ ). Vascular proliferation and hemorrhage were mostly features of bacterial infection ( $p<0.0001$  and  $p=0.02$ , respectively). Edema presence did not differ between categories ( $p=0.1$ ). Mesothelial hyperplasia was more often found with pneumothorax ( $p=0.009$ ).

The total final score was associated with the predominant macroscopic pattern ( $p=0.002$ ), as septated and hemorrhagic patterns showed the higher final score (mean  $5.2\pm0.8$  and  $6.5\pm0.7$ , respectively), followed by fibrotic, fibrinous and inflammatory (mean  $4.5\pm1.7$ ,  $4.7\pm1.3$  and  $4.4\pm1.5$ , respectively), while pleural plaques aspect showed the lower one ( $2.5\pm2.1$ ).

Vascular proliferation was significantly associated with fibrosis ( $p<0.0001$ ), as it was present in biopsies with severe and moderate fibrosis and not with mild or no fibrosis. It was also significantly associated with the type of fibrosis ( $p<0.0001$ ) as it was the cellular type that was mostly characterized by vascular proliferation. Vascular proliferation was not associated with the degree of inflammation ( $p=0.1$ ). Inflammation was not associated with the degree of fibrosis ( $p=0.08$ ).

According to these results and as illustrated in Table 4, we tried to define some patterns of NSP and their corresponding diagnostic efficacy in regards to underlying etiology (Table 5). Thus, a severely fibrotic pleura, with cellular fibrosis, vascular proliferation, hemorrhage, and neutrophils is more representative of bacterial disease (Pattern A). Lymphocyte-predominant inflammation with mild/moderate old collagenous fibrosis, with no layering or vascular proliferation, is mostly associated with viral disease (Pattern B). Moderate old collagenous fibrosis with variable degree of lymphocytic inflammation without vascular proliferation, edema, fibrin, hemorrhage or mesothelial hyperplasia is seen with heart disease (Pattern C). Autoimmune disease presents with

important cellular, layered fibrosis with moderate lymphocytic inflammation, as well as vascular proliferation, oedema and fibrin without hemorrhage (Pattern D). A similar pattern but with hemorrhage and without vascular proliferation is seen in drug-induced cases (Pattern E). In contrast to these etiologies, pleural tissue associated with recurrent pneumothorax is characterized by numerous histiocytes and eosinophils and by mild, if any, collagenous fibrosis (Pattern F). These patterns were significantly associated with the etiology ( $p < 0.0001$ ) and showed interesting values of diagnostic efficacy for each pattern (Table 5).

## **Discussion**

Non-specific pleuritis is the term usually applied to a pleural effusion after biopsy has excluded a “specific” and often definitive diagnosis, mostly malignancy or granulomatous disease (7). In this case, a descriptive diagnosis is given usually reporting features like inflammation or fibrosis (7). The etiology hidden behind this histology is variable and impossible to define without the complete clinical data. We show in this study that the various diseases presenting with a non-specific pattern in pleural biopsy differ in their detailed histological features.

In particular, bacterial diseases present predominantly with a severely fibrotic pleura and this fibrosis is cellular characteristically rich in fibroblasts. Vascular proliferation in the form of rich granulation tissue as well as hemorrhage and tissue layering are also frequent features of these infectious conditions. Furthermore, neutrophils as the predominant cellular type in pleural biopsy are almost exclusively seen with this etiological group. Indeed this pattern (A of our classification) proved to have a high positive predictive value and therefore is highly specific for bacterial infection (Table 5). Pleural effusions associated with viral infections are lymphocyte-predominant in histological specimens, showing mild or moderate fibrosis, old collagenous in type and no layering of the tissue or vascular

proliferation. This proposed pattern (Pattern B of our classification) presents high negative predictive value and sensitivity (Table 5). Pleural effusion associated with heart disease shows variable degree of inflammation but always lymphocyte-predominant and moderate fibrosis, which is mostly old collagenous without vascular proliferation, edema, fibrin, hemorrhage or mesothelial hyperplasia. The proposed pattern C in our classification showed relatively high specificity (Table 5). Autoimmune disease presents with a moderate lymphocyte-predominant inflammation, important fibrosis cellular in type and layered, as well as vascular proliferation, edema and fibrin without hemorrhage. This pattern (Pattern D) showed high negative predictive value and sensitivity (Table 5). A similar pattern but with hemorrhage and without vascular proliferation is seen in drug-induced cases. In this case, the proposed pattern E presents high specificity (Table 5). In contrast to these etiologies, pleural tissue associated with recurrent pneumothorax is characterized by an inflammation rich in histiocytes and eosinophils and by mild, if any, fibrosis that is old collagenous in type. Interestingly, this pattern classified as F proved to present the highest sensitivity and specificity for diagnosis of pneumothorax (Table 5).

These differences in histological findings provide a pattern of NSP varying according to the underlying etiology and the pathophysiology of pleural effusions. Histological changes found in the current effusions series reflect the underlying tissue remodeling seen during pleural injuries. During pleural injury, increased microvascular permeability, induces plasma extravasation and activation of tissue factor and thus initiation of coagulation and formation of fibrin (11). This disordered local fibrin turnover represents an early tissue response subject to the influence of local mediators of inflammation and of components of the fibrinolytic response and sets the stage for progressive remodeling/wound healing or fibrotic repair in the face of protracted injury (11). TGF- $\beta$  as the major pro-fibrotic factor, and subpleural fibroblasts but also mesothelial cells

that can undergo epithelial to mesenchymal (EMT)-like transition as the main cell targets, are the basic players in pleural fibrosis (11). According to our findings, bacterial and autoimmune diseases will show the most prominent remodeling of the pleural tissue probably reflecting an imbalance in favor of the coagulation and opposing to the fibrinolytic response, while viral and cardiac etiologies represent a more balanced response with less tissue remodeling. Chronic air trauma/local bleeding due to adhesions rupture in recurrent pneumothorax does not evoke an important tissue remodeling or imbalance of the fibrinolytic/coagulation system, rather evokes a foreign body reaction with eosinophils and histiocytes overloading the pleural surface.

As from a clinical point of view, NSP often presents a management dilemma for treating physician as it could represent a true benign etiology or just a sampling/diagnostic error that would then imply the need for further invasive techniques. Studies trying to answer to the question of evolution of these non-specific pleuritis cases after long-term follow-up showed that in 5% (6) to 18% (12, 13) of the cases a malignancy, particularly mesothelioma, will be revealed and thus a minimum of 1 year of clinical and imaging follow-up is recommended (8) (14) (15), as was the case in our series. Also, important criteria to facilitate the diagnosis of underlying malignancy in case of NSP are past or active history of carcinoma (16). These false-negative cases represent the difficulties in sampling a thickened pleura not allowing deep biopsies to be easily performed or a pleural cavity full of adhesions difficult to inspect (5). The endoscopic appearance of pleural lesions is suggestive of malignancy in 86% of cases and suspicious appearances include nodules, polypoid lesions, masses, malignant thickening of the pleura, and localized “candle wax drops” (17). However, benign conditions can be mistaken for malignant ones and vice versa (17). False-negative diagnoses could also represent cases difficult to handle histologically as an intense fibrosing pleuritis may difficult to discern from a

sarcomatoid or desmoplastic mesothelioma (18). We have recently shown that frozen sections in pleural disease are very efficient in rapidly diagnosing malignancy (19) and for tissue handling for molecular tests (20).

Similar with **NSP cases**, eosinophilic pleural effusions which are defined as effusions with 10% or more eosinophils, can be attributed to many causes (air or blood in the pleural cavity, malignancies, drugs, asbestos exposure, infections, or autoimmune diseases) or they can be idiopathic after exclusion of all these known etiologies (21) (22). Long-term follow-up of these “idiopathic” cases has revealed a benign clinical course but this can be reassured only after thorough thoracoscopic investigation of the pleural cavity and benign corresponding histology (21).

To conclude, our study provides the first evidence for the microscopic procedures underlying benign pleural diseases, and could lead to further investigation regarding the mechanisms driving the course of the disease. **Our classification may also be applied in the routine practice by adding a comment on the suggesting pattern in the pathology report addressed to the clinician, which can be helpful in the final diagnosis of the underlying pleural disease.** Indeed, although in our series all patients were found to present a benign disease, significant microscopic **differences** were observed reflecting the capacity for tissue remodeling in every case. It also opens new horizons for studying pleural inflammation to establish mechanisms in the pathogenesis of pleural involvement according to the underlying disease.

**Acknowledgments:** The authors would like to thank Mr Philippe Cosmo from the Tumorothèque/Centre de Ressources Biologiques de CHU Saint-Etienne (BRIF no. BB-0033-00041) for his assistance.

**Authorship contribution:** MEF conceived, designed the study, analyzed data, drafted and corrected the manuscript – GK designed the study, reviewed all pleural biopsies, drafted the manuscript – SH, FC, CB collected patients' data – FF, MP designed the study, reviewed biopsies – AP, OT, CB, MF collected thoracoscopy data – NMR drafted and corrected the manuscript. All authors reviewed and approved the final draft.

## References

1. Miserocchi G. Mechanisms controlling the volume of pleural fluid and extravascular lung water. *Eur Respir Rev*. 2009 Dec;18(114):244-52.
2. Boggs DS, Kinasewitz GT. Review: pathophysiology of the pleural space. *Am J Med Sci*. 1995 Jan;309(1):53-9.
3. Froudarakis ME. Diagnostic work-up of pleural effusions. *Respiration*. 2008;75(1):4-13.
4. Venekamp LN, Velkeniers B, Noppen M. Does 'idiopathic pleuritis' exist? Natural history of non-specific pleuritis diagnosed after thoracoscopy. *Respiration*. 2005 Jan-Feb;72(1):74-8.
5. Janssen JP, Ramlal S, Mravunac M. The Long-Term Follow Up of Exudative Pleural Effusion After Nondiagnostic Thoracoscopy. *J Bronchol*. 2004;11((3)):169-74.
6. Ferrer JS, Munoz XG, Orriols RM, Light RW, Morell FB. Evolution of idiopathic pleural effusion: a prospective, long-term follow-up study. *Chest*. 1996 Jun;109(6):1508-13.
7. Davies HE, Nicholson JE, Rahman NM, Wilkinson EM, Davies RJ, Lee YC. Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies. *Eur J Cardiothorac Surg*. 2010 Oct;38(4):472-7.
8. DePew ZS, Verma A, Wigle D, Mullon JJ, Nichols FC, Maldonado F. Nonspecific pleuritis: optimal duration of follow-up. *Ann Thorac Surg*. 2014 Jun;97(6):1867-71.
9. Colt HG, Russack V, Chiu Y, Konopka RG, Chiles PG, Pedersen CA, et al. A comparison of thoracoscopic talc insufflation, slurry, and mechanical abrasion pleurodesis. *Chest*. 1997 Feb;111(2):442-8.
10. Froudarakis ME, Greillier L, Monjanel-Mouterde S, Koutsopoulos A, Devictor-Pierre B, Guilhaumou R, et al. Intrapleural administration of lipoplatin in an animal model. *Lung Cancer*. 2010 Apr;72(1):78-83.
11. Mutsaers SE, Prele CM, Brody AR, Idell S. Pathogenesis of pleural fibrosis. *Respirology*. 2004 Nov;9(4):428-40.
12. Yang Y, Wu YB, Wang Z, Wang XJ, Xu LL, Tong ZH, et al. Long-term outcome of patients with nonspecific pleurisy at medical thoracoscopy. *Respir Med*. 2017 Mar;124:1-5.
13. Metintas M, Ak G, Cadirci O, Yildirim H, Dundar E, Metintas S. Outcome of patients

diagnosed with fibrinous pleuritis after medical thoracoscopy. *Respir Med.* 2012 Aug;106(8):1177-83.

14. Bhatnagar R, Corcoran JP, Maldonado F, Feller-Kopman D, Janssen J, Astoul P, et al. Advanced medical interventions in pleural disease. *Eur Respir Rev.* 2016 Jun;25(140):199-213.

15. Anevllavis S, Froudarakis ME. Advances in pleuroscopy. *Clin Respir J.* 2016 Mar;12(3):839-47.

16. Vakil E, Ost D, Vial MR, Stewart J, Sarkiss MG, Morice RC, et al. Non-specific pleuritis in patients with active malignancy. *Respirology.* 2018 Feb;23(2):213-9.

17. Chrysanthidis MG, Janssen JP. Autofluorescence videothoracoscopy in exudative pleural effusions: preliminary results. *Eur Respir J.* 2005 Dec;26(6):989-92.

18. Karpathiou G, Stefanou D, Froudarakis ME. Pleural neoplastic pathology. *Respir Med.* 2015 Aug;109(8):931-43.

19. Karpathiou G, Froudarakis M, Forest F, Mobarki M, Patoir A, Gay P, et al. Frozen Sections in Pleural Pathology: A Valuable Tool. *Respiration.* 2017;94(1):45-51.

20. Karpathiou G, Batistatou A, Forest F, Clemenson A, Peoc'h M. Basic Molecular Pathology and Cytogenetics for Practicing Pathologists: Correlation With Morphology and With a Focus on Aspects of Diagnostic or Therapeutic Utility. *Adv Anat Pathol.* 2016 Nov;23(6):368-80.

21. Archontogeorgis K, Anevllavis S, Zarogoulidis P, Jain A, Karpathiou G, Giatromanolaki A, et al. Pleuroscopy in 'Idiopathic' eosinophilic pleural effusions. *Clin Respir J.* 2015 Oct;9(4):475-80.

22. Voulgaris T, Anevllavis S, Karpathiou G, Forest F, Koulelidis A, Froudarakis M. Dabigatran can cause eosinophilic pleural and pericardial effusion with blood eosinophilia. *Clin Respir J.* 2016 Feb;12(2):799-801.

**Table 1. Patients characteristics (n=100)**

	n, (%)
<b>Age (years)</b>	
Median	63
Range	13-94
<b>Sex</b>	
Male	71 (71)
Female	29 (29)
<b>Follow up (months)</b>	
Median	36
Range	1-48
<b>Final aetiology</b>	
- Pneumothorax	28 (28)
- Bacterial Infection	27 (27)
- Cardiac	10 (10)
- Drug induced	7 (7)
- Viral Infection	7 (7)
- Auto-immune disease	5 (5)
- Other	16 (16%)
Surgery-trauma	2
Pleural plaque	2
Dressler	1
Kidney failure	1
Pulmonary embolism	1
Radiotherapy	1
Chylothorax	1
Eosinophilic	1
Unkown-idiopathic	6
<b>Localization</b>	
Left	44 (44)
Right	42 (42)
Bilateral	11 (11)
<b>Predominant pleural aspect during thoracoscopy</b>	
Inflammatory	40 (40)
Fibrinous	14 (14)
Fibrous	6 (6)
Septated	8 (8)
Hemorrhagic	2 (2)
Pleural plaques	2 (2)

**Table 2. Histological evaluation in all patients except “Other” group (n=84)**

Parameters	n (%)
<b>Inflammation</b>	
No	7 (8.4)
Mild	23 (27.7)
Moderate	41 (49.3)
Severe	12 (14.4)
<b>Predominant inflammatory cell type (n=76)</b>	
Lymphocytes	49 (64.4)
Plasmocytes	10 (13.1)
Neutrophils	9 (11.8)
Histiocytes	7 (9.2)
Eosinophils	1 (1.3)
<b>Fibrosis</b>	
No	7 (8.4)
Mild	30 (36.1)
Moderate	19 (22.8)
Severe	27 (32.5)
<b>Type of fibrosis (n=76)</b>	
Cellular	29 (38.1)
Old	39 (51.3)
Both	8 (10.5)
<b>Layering</b>	
Yes	28 (33.8)
No	55 (66.2)
<b>Vascular proliferation</b>	
Yes (score 2 and 3)	41 (49.3)
No (score 0 and 1)	42 (50.6)
<b>Oedema</b>	
Yes (score 2 and 3)	17 (20.4)
No (score 0 and 1)	66 (79.5)
<b>Haemorrhage</b>	
Yes (score 2 and 3)	19 (23.1)
No (score 0 and 1)	63 (76.8)
<b>Fibrin</b>	
Yes (score 2 and 3)	34 (40.9)
No (score 0 and 1)	49 (59.1)
<b>Mesothelial Hyperplasia</b>	
Yes (score 2 and 3)	11 (13.2)
No (score 0 and 1)	72 (86.7)
<b>Number of slides examined per case</b>	
Median (range)	4 (1-18)
<b>Specimen size (cm)</b>	
Median (range)	7 (1-28)
<b>Histiocytes</b>	
Yes	24 (28.8)
No	59 (71.2)

**Table 3. Clinicopathologic correlations**

	Bacterial n=27	Viral n=7	Cardiac n=10	Pneumo- thorax n=28	Auto- immune n=5	Drug n=6	p
<b>Final score (mean)</b>	5.1±1.4	4.4±1.6	3.8±1.2	3.1±1.5	5.6±1.1	4±1.4	<b>&lt;0.0001</b>
<b>Inflammation</b>							
No	3	1	0	3	0	0	0.3
Mild	6	0	3	11	0	3	
Moderate	12	4	5	13	5	2	
Severe	6	2	2	1	0	0	
<b>Predominant inflammatory cell type</b>							
Lymphocytes	14	7	9	11	5	4	0.02
Plasmocytes	3	0	1	5	0	1	
Neutrophils	7	0	0	1	0	1	
Histiocytes	0	0	0	7	0	0	
Eosinophiles	0	0	0	1	0	0	
<b>Fibrosis</b>							
No	2	0	2	2	0	1	0.03
Mild	3	3	3	18	0	2	
Moderate	6	2	2	6	2	1	
Severe	15	2	3	2	3	2	
<b>Type of fibrosis</b>							
Cellular	17	1	3	5	1	2	0.006
Old	5	5	4	20	2	3	
Both	3	1	1	1	2	0	
<b>Layering</b>							
Yes	13	1	4	4	3	3	0.05
No	14	6	6	24	2	3	
<b>Vascular proliferation</b>							
Yes (score 2 and 3)	24	3	3	7	3	1	<0.0001
No (score 0 and 1)	3	4	7	21	2	5	
<b>Oedema</b>							
Yes (score 2 and 3)	7	1	0	4	2	3	0.1
No (score 0 and 1)	20	6	10	24	3	3	
<b>Fibrin</b>							
Yes (score 2 and 3)	16	2	3	7	3	3	0.1
No (score 0 and 1)	11	5	7	21	2	3	
<b>Heamorrhage</b>							
Yes (score 2 and 3)	12	1	2	2	0	2	0.02
No (score 0 and 1)	15	6	8	25	5	4	
<b>Presence of histiocytes</b>							
Yes	0	3	1	20	0	0	<0.0001
No	27	4	9	8	5	6	
<b>Mesothelial hyperplasia</b>							
Yes	0	1	0	9	0	1	0.009
No	27	6	10	19	5	5	

**Table 4. Histological features according to etiology**

	<b>Bacterial</b>	<b>Viral</b>	<b>Cardiac</b>	<b>Pneumothorax</b>	<b>Autoimmune</b>	<b>Drug</b>
<b>Inflammation</b>	++/+++	++/+++	+ / ++	+ / ++	++	+ / ++
<b>Lymphocytes</b>	++	++	++	++	++	++
<b>Plasmacytes</b>	+	-	-	+	-	-
<b>Neutrophils</b>	++	-	-	-	-	-
<b>Histiocytes</b>	-	-	-	++	-	-
<b>Eosinophils</b>	-	-	-	++	-	-
<b>Fibrosis</b>	+++	+ / ++	++	+ / -	+++	+ / -
<b>Cellular fibrosis</b>	+++	+ / -	+ / -	+ / -	+ / -	+ / -
<b>Layering</b>	+++	+ / -	+	+ / -	+++	+++
<b>Vascular proliferation</b>	+++	++	+	+ / -	+	+ / -
<b>Oedema</b>	+	+ / -	-	+ / -	+ / -	+
<b>Fibrin</b>	+++	+ / -	+ / -	+ / -	++	++
<b>Haemorrhage</b>	+++	+ / -	+ / -	+ / -	-	+ / -
<b>Mesothelial hyperplasia</b>	-	+ / -	-	++	-	+ / -

-: absent, +: mildly present, ++: moderately present, +++: usually present.

**Table 5. Efficacy of the proposed patterns for dignosing the underlying cause**

	<b>Pattern A= Bacterial</b>	<b>Pattern B= Viral</b>	<b>Pattern C= Cardiac</b>	<b>Pattern D= Autoimmune</b>	<b>Pattern E= Drug</b>	<b>Pattern F= Pneumothorax</b>
<b>PPV</b>	100%	35%	20%	21.74%	57.14%	90.32%
<b>NPV</b>	84.88%	100%	90.53%	100%	96.77%	100%
<b>Sensitivity</b>	51.85%	100%	10%	100%	57.14%	100%
<b>Specificity</b>	100%	86.02%	95.56%	81.05%	96.77%	95.83%

**PPV: positive predictive value**

**NPV: negative predictive value**

## **Figures legends**

**Figure 1. Fibrosis histological assessment.** **A/** A normal parietal pleura biopsy showing mesothelial cells and the underlying connective tissue with its vascular elements (HES x 200). **B/** Mild collagenous fibrosis overlying parietal pleura adipose tissue and mild lymphocytic inflammation of a heart-disease associated NSP (HES x 50). **C/** Moderate collagenous fibrosis overlying parietal pleura adipose tissue in a case of a heart-disease associated NSP (HES x 40). **D/** Severe cellular fibrosis replacing the whole pleural membrane accompanied by hemorrhage on the cavity surface in a bacterial NSP (HES x 20).

**Figure 2. Stages during inflammation/wound healing in bacterial-caused NSP.** **A/** A biopsy showing prominent tissue layering: the initial pleural membrane with overlying inflammation (blue line), edema (red line) and vascular-rich organization tissue (black line)(HES x 20). **B/** Another case of tissue organization, showing conspicuous vascular proliferation inside a fibrotic and inflammatory stroma (HES x 40). **C/** The typical morphology of a fibroblast-rich fibrosis with layering of cells (HES x 200). **D/** For comparison, a case of viral-induced NSP showing old collagenous fibrosis at the bottom with a mildly cellular fibrosis at more superficial levels (mixed fibrosis, HES x 100).

**Figure 3. Representative patterns of NSP.** **A/** Bacteria-associated NSP showing a thickened layered fibrotic pleura with rich cellular fibrosis, inflammation and hemorrhage at the surface (HES x 40). **B/** A viral-associated NSP showing moderate chronic inflammation, mild mesothelial hyperplasia and no fibrosis (HES x 100). **C/** A cardiac NSP showing moderate old fibrosis and mild inflammation (HES x 40). **D/** A pneumothorax-associated NSP showing a mild old collagenous fibrosis and a rich histiocytic infiltrate often with giant cells and eosinophiles leucocytes (HES x 100).

HES: Hematoxylin, Eosin, Saffran

NSP: Non-specific pleuritis